[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-386484-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-386484-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deprescribing-a-prime-opportunity-to-optimize-care-of-cancer-patients","Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients","","Patients with incurable cancers often develop multiple comorbidities, increasing the likelihood of polypharmacy and its harms, including drug-to-drug interactions, potentially inappropriate prescribing, and adverse drug events. Deprescribing is a patient-centered approach that discontinues medications no longer necessary or potentially inappropriate to improve outcomes. It can enhance quality of life, reduce side-effect and poorer-outcome risks, and lower healthcare costs while aligning medication decisions with patient values, preferences, and goals of care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deprescribing-a-prime-opportunity-to-optimize-care-of-cancer-patients/386484/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deprescribing-a-prime-opportunity-to-optimize-care-of-cancer-patients/386484.png","ImageObject",300,407,{"name":42,"@type":43},"Aldword","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is deprescribing in patients with incurable cancer?","Question",{"text":63,"@type":64},"Deprescribing is a systematic, patient-centered process of identifying and discontinuing medications when potential harms outweigh potential benefits.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why does polypharmacy increase risk for cancer patients?",{"text":68,"@type":64},"Polypharmacy can raise the likelihood of drug-to-drug interactions, potentially inappropriate medication use, and adverse drug events, which may also worsen quality of life.",{"name":70,"@type":61,"acceptedAnswer":71},"How does deprescribing connect to advance care planning?",{"text":72,"@type":64},"Both processes require attention to patients' values, preferences, and care goals, enabling discussions about goals of care in advanced cancer or limited life expectancy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},386484,1790742121,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Commentary  \nDeprescribing: A Prime Opportunity to Optimize Care of Cancer Patients  \nGenevieve Chaput * and Hitesh Bhanabhai  \nCitation: Chaput, G.; Bhanabhai, H.  \nDeprescribing: A Prime Opportunity to Optimize Care of Cancer Patients. Curr. Oncol. 2023, 30, 9701–9709 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol30110704  \nReceived: 18 August 2023  \nRevised: 21 October 2023  \nAccepted: 30 October 2023  \nPublished: 2 November 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDivision of Supportive and Palliative Care, McGill University Health Centre, Department of Family Medicine, McGill University, Montreal, QC H4A 3J1, Canada  \n* Correspondence: [genevieve.chaput@mcgill.ca](genevieve.chaput@mcgill.ca)  \nAbstract: Patients with incurable cancers have an increasing number of comorbidities, which can lead to polypharmacy and its associated adverse events (drug-to-drug interaction, prescription of a potentially inappropriate medication, adverse drug event) . Deprescribing is a patient-centered process aimed at optimizing patient outcomes by discontinuing medication(s) deemed no longer necessary or potentially inappropriate. Improved patient quality of life, risk reduction of side effects or worse clinical outcomes, and a decrease in healthcare costs are well-documented benefits of deprescribing. Deprescribing and advance care planning both require consideration of patients'values, preferences, and care goals. Here, we provide an overview of comorbidities and associated polypharmacy risks in cancer patients, as well as useful tools and resources for deprescribing in daily practice, and we shed light on how deprescribing can facilitate advance care planning discussions with patients who have advanced cancer or a limited life expectancy.  \nKeywords: deprescribing; goals of care; polypharmacy; advance care planning; comorbidities; patient-centered care  \n1. Introduction  \nCancer patients are often afflicted with other chronic comorbid conditions [1] . Aspharmacological agents are routinely required in the management of comorbid conditions, polypharmacy is often observed in patients afflicted with cancer [2,3] . While clinical guidelines to managing comorbid conditions can promote the use of more than one medication to optimize patient outcomes, polypharmacy puts patients at increased risk of experiencing a drug-to-drug interaction [4], being prescribed a potentially inappropriate medication, or developing an adverse drug event [5,6] . More specifically, in advanced cancer and palliative care settings, unpredictable variations in medication pharmacokinetics and pharmacodynamics can occur, leading to decreased medication tolerance and burdensome side effects, which can be mistakenly believed to be due to the underlying disease [7] . Deprescribing, defined as the systematic process of identifying and discontinuing medications in circumstances in which existing or potential harms are greater than existing or potential benefits [8], can serve as a pivotal teaching moment in clinical practice by which to initiate, explore, or reassess the goals of care with respect to advanced cancer patients [9] . Asthe process of deprescribing requires the consideration of a patient's care goals, values, preferences, functional level, and expected prognosis [8], advance care planning should bean integral part of deprescribing discussions with these patients [9] . This article provides an overview of the comorbidities and associated polypharmacy risks in the cancer population, as well as the available tools and resources designed to aid deprescribing in clinical practice, and illustrates how deprescrib","cbCaiusLMZOs6EOH","https://ap.wps.com/l/cbCaiusLMZOs6EOH","pdf",239154,"English","# Introduction\n# Discussion\n## Comorbidities and Associated Polypharmacy Risks in Cancer Patients","[{\"question\":\"What is deprescribing in patients with incurable cancer?\",\"answer\":\"Deprescribing is a systematic, patient-centered process of identifying and discontinuing medications when potential harms outweigh potential benefits.\"},{\"question\":\"Why does polypharmacy increase risk for cancer patients?\",\"answer\":\"Polypharmacy can raise the likelihood of drug-to-drug interactions, potentially inappropriate medication use, and adverse drug events, which may also worsen quality of life.\"},{\"question\":\"How does deprescribing connect to advance care planning?\",\"answer\":\"Both processes require attention to patients' values, preferences, and care goals, enabling discussions about goals of care in advanced cancer or limited life expectancy.\"}]","Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients | PDF",1790273977,23]